泰福生技完成董事會改組　保瑞集團董事長盛保熙出任新董座

Tanvex Completes Board Re-election, Bora Pharmaceuticals Chairman Bobby Sheng Appointed As New Chairman

台北，台灣，2025 年 3 月 27 日－泰福生技股份有限公司（以下簡稱「泰福生技」，台灣證券交易所股票代碼：6541）今日宣布完成董監改選，董事於臨時股東會後的董事會中推選保瑞集團董事長盛保熙先生為泰福生技董事長，董事會由保瑞集團四席（含二席保瑞提名之獨董）、潤泰集團三席（含二席潤泰提名之獨董）、Delos Capital Fund 代表人陳林正先生一席、創辦人趙宇天博士一席組成。

Taipei, Taiwan, March 27, 2025 – Tanvex BioPharma, Inc. ("Tanvex", 6541.TW), today announced the completion of its board re-election. Following the extraordinary shareholders' meeting, the new Board has appointed Bobby Sheng, Chairman of Bora Group, as Chairman of Tanvex BioPharma. The new board comprises four seats from Bora Group (including two Independent Directors nominated by Bora Group), three seats from Ruentex Group (including two Independent Directors nominated by Ruentex), and one seat each from Delos Capital Fund and Tanvex founder Dr. Allen Chao.

泰福生技董事長盛保熙表示：「隨著大分子製程技術佈建完成，搭配無菌針劑充填廠，我們已建立起完整的一站式（end-to-end）製造能力。特別是在生技新藥開發的早期階段，能提供高度靈活且以客戶為中心的服務，是我們與客戶攜手成長的重要優勢。目前全球通過美國 FDA 查廠、具備商業化大分子量產能力的產能仍屬稀缺，而我們在美國聖地牙哥的 cGMP 廠正是其中之一。在當前政治與貿易風險升溫的敏感時刻，這項優勢將使我們成為國際生技客戶的戰略夥伴。」

Commenting on his new role, Tanvex Chairman Bobby Sheng said, "As Tanvex fulfills the large molecule substance CDMO capabilities of Bora Group, paired with our sterile injectable fill-finish facility, we have established a fully integrated end-to-end manufacturing platform. Especially during the early-stage development of biologic drugs, our ability to provide highly flexible, customer-centric solutions is a key advantage that enables us to grow alongside our clients. Globally, commercial-scale large molecule manufacturing sites that have passed U.S. FDA inspections remain limited. Our cGMP facility in San Diego stands as one of the few. At a time when political and tariff risks are on the rise, this capability positions us as a strategic partner for global biotech companies seeking reliable, resourceful, U.S.-based production capacity."

本次改選泰福生技執行長 Stephen Lam 亦進入董事會，他表示：「自 1 月 20 日與保瑞集團正式合併完成後，我們積極整合原保瑞生技與泰福生技的資源，並承襲在 CDMO 市場已有成功經驗的 Bora Biologics 這個品牌，初步已見到正向發展，第一季的 CDMO 客戶需求提案(Request For Proposal)超過 10 個、並有多個後期商業量產的業務詢問，創下新高。」整合後的 Bora Biologics CDMO 能量已跨入多特異性免疫檢查點 T 細胞銜接抗體(multi-specific)等新型態抗體 pre-IND 階段開發，而抗體藥物複合體(Antibody-Drug Conjugates, ADC) 技術平台也在竹北廠完成擴建後逐步完善，Stephen Lam 說：「我們

相信泰福生技將能運用保瑞集團的全球資源、更積極有效地回應產業需求的變化；在美國本土的商業量產產能炙手可熱的關鍵時期，我們將攜手為客戶在生物製劑開發中提供獨一無二的支持服務與創新動能。」

Stephen Lam, CEO of Tanvex BioPharma, who also joins the Board upon the re-election, commented, "Since the Tanvex-Bora Group alliance was officially formed on January 20th, we have been actively integrating resources of two companies under the established and trusted Bora Biologics brand, which has a strong track record in the CDMO space. The results are already promising — in the first quarter alone, we received more than 10 CDMO RFPs, marking a record high." Following the integration, Bora Biologics' CDMO capabilities have now expanded into cutting-edge modalities such as multi-specific T-cell engager antibodies in pre-IND development, while the antibody-drug conjugate (ADC) platform has steadily progressed following the expansion of our Hsinchu site.

Stephen added, "We believe that Tanvex, backed by Bora Group's global network, is well positioned to respond swiftly and effectively to evolving industry needs. At a time when U.S.-based commercial-scale manufacturing capacity is in extremely high demand, we are committed to delivering unique support and innovation to our biopharma partners in their biologics development journey."

關於泰福生技

泰福生技股份有限公司（台灣證券交易所：6541）成立於2011年，其使命是通過使生物製劑更加經濟實惠且提高可取得性來革新全球醫藥產業。多年來，泰福生技在生物製劑開發和製造方面不斷精進專業知識，最終成功實現了第一個產品的商業化。隨著另一個生物製劑許可申請（BLA）正等待美國FDA批准，泰福生技的發展歷程體現了對卓越、創新的堅定承諾，以及改善患者醫藥服務的熱忱。泰福生技致力於推進醫療保健，這促使其以「Bora Biologics」的品牌擴展了作為CDMO的能力。整併前的保瑞生技已擁有超過70批成功的cGMP製造記錄，為全球生物製藥公司提供靈活、全面的一站式服務方案，在確保品質的同時、提高時間和成本效率。通過利用其全球CDMO能力、美國FDA核准通過的先進設施，以及在生物製劑開發和製造方面的深厚專業知識，保瑞生技為其客戶確保了高效且有效的市場進入途徑。

About Tanvex and Bora Biologics

Tanvex BioPharma, Inc. (TWSE: 6541), was founded in 2011 with a mission to revolutionize the healthcare industry by making biologics more affordable and accessible to patients. Over the years, Tanvex has honed its expertise in biologics development and manufacturing, culminating in the successful commercialization of our first product. With another Biological License Application (BLA) pending U.S. FDA approval, Tanvex's journey is characterized by an unwavering commitment to excellence, innovation, and a passion for improving patient care.

Tanvex's commitment to advancing healthcare has led to the expansion of its capabilities as a CDMO under the name Bora Biologics. With a proven track record of over 100 successful

cGMP manufacturing batches, Bora Biologics provides agile, comprehensive end-to-end solutions that enhance time and cost efficiencies for biopharma companies worldwide. By leveraging its global CDMO capabilities, state-of-the-art, FDA-registered facility in the U.S., and deep expertise in biologics development and manufacturing, Bora Biologics ensures efficient and effective pathways to market for its clients.

【新聞聯絡人】

泰福生技 欒君儀 Angela Luan: angela.luan@tanvex.com 0922-407094